Comparative study of the effect of intravitreal injection of bevacizumab versus simultaneous intravitreal injection of bevacizumab and triamcinolone acetonide

Comparative study of the effect of intravitreal injection of bevacizumab versus simultaneous intravitreal injection of bevacizumab and triamcinolone acetonide in patients with retinal venous occlusion

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N185

Enrollment

Registered

2022-05-25

Start date

2022-04-14

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vascular occlusions. Retinal vascular occlusions

Interventions

Intervention 1: In the first intervention group, an intravitreal injection of 1.25 mg/0.05 mL bevacizumab (Darou Pakhsh Company) will be performed monthly for six months. Intervention 2: In the second

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who have had retinal vein occlusion in the last 12 weeks based on their history

Exclusion criteria

Exclusion criteria: History of any previous treatment, including macular laser or intravitreal injection Having ocular hypertension Vision better than 20/40 or central macular thickness less than 250 microns Media opacity Any type of neovascularization or with retinal arterial occlusion or symptoms in favor of treatment such as cilioretinal and retinal shunts Any retinal disease

Design outcomes

Primary

Measure	Time frame
Vision. Timepoint: First, one and six months after the end of the study. Method of measurement: using Snellen eye chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Kariminia

Kermanshah University of Medical Sciences

masume.kariminia1368@gmail.com+98 83 3727 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026